uniQure (QURE) Receives a Buy from RBC Capital
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on uniQure (QURE – Research Report), with a price ...
uniQure’s AMT-130 Program Shows Promise for Accelerated Approval and Stock Growth
TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating today. Joseph Thome’s rating is ...
pharmaphorum1mon
bluebird offers instalment payments for Zynteglo gene therapy
The first gene therapy to reach the market – UniQure’s Glybera for rare disease lipoprotein lipase deficiency (LPLD) – tried the high upfront cost approach but failed commercially and was ...